Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
A phase 3 trial of Trastuzumab and Trastuzumab biosimilars in Ductal carcinoma in situ, run by National Cancer Institute (NCI), completed.
Overview
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy is a phase 3 interventional study registered as NCT00769379 by National Cancer Institute (NCI), with 2014 participants recorded, started 2008-12-10 and reaching its primary completion in 2019-12-31. Interventions recorded: Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation. Conditions recorded: Breast Ductal Carcinoma In Situ.
Linked to the drug Trastuzumab biosimilars because the registry names it among its interventions and Ductal carcinoma in situ among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Trastuzumab and the tag pipeline.
- TrialA Study of DB-1310 in Advanced/Metastatic Solid Tumors
Shares Trastuzumab and the tag pipeline.
- TrialOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Shares Trastuzumab and the tag pipeline.
- TrialTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Shares Trastuzumab and the tag pipeline.
- TrialMargetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Shares Trastuzumab and the tag pipeline.